Proton Pump Inhibitors in the Management of GERD

被引:29
作者
Katz, Philip O. [1 ]
Zavala, Stacey [1 ]
机构
[1] Thomas Jefferson Univ, Jefferson Med Coll, Albert Einstein Med Ctr, Philadelphia, PA 19107 USA
关键词
Proton pump inhibitors; GERD; Pharmacologic properties; GASTROESOPHAGEAL-REFLUX DISEASE; NOCTURNAL GASTRIC-ACIDITY; ESOMEPRAZOLE; 40; MG; EROSIVE ESOPHAGITIS; ORAL SUSPENSION; OMEPRAZOLE; RISK; BREAKTHROUGH; THERAPY; ARTICLE;
D O I
10.1007/s11605-009-1015-3
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction Management of gastroesophageal reflux disease (GERD) is based on the concept that gastric contents, principally acid and pepsin, are responsible for symptoms of reflux and esophageal injury. Pharmacologic treatment is based on the principle that controlling intragastric pH will affect esophageal healing and subsequently symptom relief. Results and Discussion Control of pH can be accomplished with antisecretory agents, principally proton pump inhibitors (PPIs). The majority of patients respond to a single daily dose of a PPI; however, some will require higher doses, and a small percentage are "refractory" to twice daily dosing of these drugs. The success of these agents, and in fact the reasons for "failure," is elucidated by understanding the mechanism of action of PPIs and the effect of dose timing and meals on their efficacy. Conclusion Awareness of new concerns regarding potential side effects of PPIs when used long-term require careful thought as GERD is a chronic disease with most needing some form of medical treatment over time. This article reviews the pharmacologic properties of PPIs and the impact on the treatment of GERD.
引用
收藏
页码:62 / 66
页数:5
相关论文
共 29 条
[11]   Helicobacter pylori infection influences nocturnal gastric acid breakthrough [J].
Katsube, T ;
Adachi, K ;
Kawamura, A ;
Amano, K ;
Uchida, Y ;
Watanabe, M ;
Kinoshita, Y .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (08) :1049-1056
[12]   Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis [J].
Katz, P. O. ;
Ginsberg, G. G. ;
Hoyle, P. E. ;
Sostek, M. B. ;
Monyak, J. T. ;
Silberg, D. G. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (05) :617-628
[13]   Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms [J].
Katz, P. O. ;
Koch, F. K. ;
Ballard, E. D. ;
Bagin, R. G. ;
Gautille, T. C. ;
Checani, G. C. ;
Hogan, D. L. ;
Pratha, V. S. V. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (02) :197-205
[14]   Long-term omeprazole treatment in resistant gastroesophageal reflux disease:: Efficacy, safety, and influence on gastric mucosa [J].
Klinkenberg-Knol, EC ;
Nelis, F ;
Dent, J ;
Snel, P ;
Mitchell, B ;
Prichard, P ;
Lloyd, D ;
Havu, N ;
Frame, MH ;
Romàn, J ;
Walan, A .
GASTROENTEROLOGY, 2000, 118 (04) :661-669
[15]   PHARMACOLOGICAL MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE [J].
KLINKENBERGKNOL, EC ;
FESTEN, HPM ;
MEUWISSEN, SGM .
DRUGS, 1995, 49 (05) :695-710
[16]   A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis:: the EXPO study [J].
Labenz, J ;
Armstrong, D ;
Lauritsen, K ;
Katelaris, P ;
Schmidt, S ;
Schütze, K ;
Wallner, G ;
Juergens, H ;
Preiksaitis, H ;
Keeling, N ;
Nauclér, E ;
Eklund, S .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (06) :739-746
[17]   Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs [J].
Laheij, RJF ;
Sturkenboom, MCJM ;
Hassing, RJ ;
Dieleman, J ;
Stricker, BHC ;
Jansen, JBMJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (16) :1955-1960
[18]  
Lew EA, 1999, ALIMENT PHARM THERAP, V13, P11
[19]   Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota [J].
Locke, GR ;
Talley, NJ ;
Fett, SL ;
Zinsmeister, AR ;
Melton, LJ .
GASTROENTEROLOGY, 1997, 112 (05) :1448-1456
[20]  
MASSOOMI F, 1993, PHARMACOTHERAPY, V13, P46